Investor Presentaiton

5 Investor presentation Full year 2022 Sales growth of 16% driven by both operating units Novo NordiskⓇ Reported geographic sales split for the full year 2022 Reported therapy area sales and growth for the full year 2022 DKK Insulin GLP-1 billion Obesity care Rare disease Other diabetes Growth at CER DKK North America Operations International Operations billion Growth at CER 200 100 21% 13% 16% 42% -11% 84% 1% 88 80 60 60 40 40 20 20 150 International Operations 13% 15% 100 24% 50 -6% 50 IO -7% 57% NAO -21% 21% NAO 36% ΙΟ 82% 85% IO 5% NAO -5% 0 0 NAO IO EMEA China ROW Total 1 GLP-1 Insulin Obesity care Rare disease IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; ROW: Rest of World; NAO: North America Operations Note: Unless otherwise specified, sales growth rates are at CER 1 'Other diabetes' is included in Total

View entire presentation